Navigation Links
Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
Date:1/12/2009

ing his presentation, Mr. Watkins will discuss the following goals and updates on progress.

LATE-STAGE PRODUCTS

Albuferon(R): Met Primary Endpoint in Phase 3 Trial in Genotypes 2 and 3 Chronic Hepatitis C; Phase 3 Results in Genotype 1 Patients Expected March 2009

In December 2008, HGS reported that the results of ACHIEVE 2/3 demonstrated that Albuferon (albinterferon alfa-2b) met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) in this global Phase 3 trial in 933 treatment-naive patients with genotypes 2 and 3 chronic hepatitis C (p=0.0086). The data showed that the rate of sustained virologic response was comparable for the 900-mcg dose of Albuferon administered every two weeks, vs. the standard 180-mcg dose of peginterferon alfa-2a administered once weekly. Rates of serious adverse events, severe adverse events and discontinuations due to adverse events were also comparable. The results of ACHIEVE 1, the Phase 3 trial of Albuferon in genotype 1 chronic hepatitis C, are expected in March 2009. Albuferon is being developed by HGS and Novartis under an exclusive worldwide co-development and commercialization agreement entered into in June 2006.

"The data from ACHIEVE 2/3 show that the efficacy of Albuferon was comparable to Pegasys, with half the injections," said Mr. Watkins. "If Albuferon is also successful in ACHIEVE 1, we expect that global marketing applications will be filed in fall 2009 - and we believe Albuferon could become the market-leading interferon for the treatment of chronic hepatitis C,"

In a separate press release issued this morning, HGS announced that Novartis has initiated a Phase 2b trial to evaluate the safety and efficacy of Albuferon dosed monthly in treatment-naive patients with genotypes 2 and 3 chronic hepatitis C.

Key goals for Albuferon in 2009:

  • Report
    '/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... 04, 2015 Research ... addition of the "MRI Systems Market to ... Efficiency, with Growth Driven by Developing Economies" ... Market to 2020 - Focus on Patient Comfort ... Economies" discusses the market, competitive landscape, and trends ...
(Date:8/4/2015)... and LOS ANGELES , Aug. ... DGX ), the world,s leading provider of diagnostic ... the previously announced acquisition of MemorialCare Health System,s ... a result of the transaction, patients and physicians ... innovative services and network of nearly 200 patient ...
(Date:8/4/2015)... Pharma, Inc. (Nasdaq: MEIP ), an oncology company focused ... today that Daniel P. Gold , Ph.D., President and ... Healthcare Conference on Tuesday, August 11, 2015 at 3:40 p.m. ... New York . A live webcast of the ... will be available approximately one hour after the presentation. ...
Breaking Medicine Technology:Global MRI Systems Market Outlook to 2020 - Focus on Patient Comfort and Operational Efficiency, with Growth Driven by Developing Economies 2Quest Diagnostics Completes Acquisition of MemorialCare Health System's Laboratory Outreach Service Business in Southern California 2MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... Sosei Group Corporation,("Sosei"; TSE Mothers Index: 4565), ... Japanese Phase III clinical trial for the,emergency contraceptive ... rights to the product in Japan from HRA ... evaluate the safety and prevented,pregnancy rate of SOH-075 ...
... Americans, WASHINGTON, July 9 In a congressional,hearing ... the,safety and importance of the research programs operated by ... absolute commitment to its patients,while expressing regret that even ... "VA has an outstanding research program, and has been ...
Cached Medicine Technology:Sosei Announces Completion of Phase III Trial for NorLevo(R) 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 2Secretary Reinforces VA's Commitment to Research Safety and Veteran Focus 3
(Date:8/4/2015)... ... August 04, 2015 , ... How cool is it to check in at ... The new "Now" feature will soon allow you to do just that. , Ahhaa ... other using the now feature. , Users will soon get to share what inspires ...
(Date:8/4/2015)... ... 2015 , ... World Patent Marketing, a vertically integrated manufacturer ... invention that eliminates the need to have a partner or trainer when using ... worth $30 billion," says Scott Cooper, CEO and Creative Director of World Patent ...
(Date:8/4/2015)... WASHINGTON, D.C. (PRWEB) , ... August 04, 2015 ... ... issues fellowship focused on sexual and reproductive health and rights in Indonesia for ... Journalists will visit a number of sites in Indonesia and attend the International ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... An ... that found financial incentives to be a viable method for encouraging people to lose ... money on the future of their weight loss success, adding a financial incentive to ...
(Date:8/4/2015)... CA (PRWEB) , ... August 04, 2015 , ... ... are suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, ... the only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands ...
Breaking Medicine News(10 mins):Health News:Ahhaa App Soon to Release the "Now" Feature 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 2Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 3Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 4Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 5Health News:As The Navy Changes Body-Fat Rules, the World Patent Marketing Review Team Announces the Development of the Assisted Dumbbell Bench Rack 6Health News:UN Foundation Announces Press Fellowship to Indonesia with Focus on Women’s Health and Rights 2Health News:Article on Incentivizing Weight Loss Mirrors Similar Motivations Surrounding Weight Loss Surgery, Says Dr. Feiz & Associates 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3
... , , VOORHEES, N.J., Sept. ... involving the skin, visceral organs, and airway, causing discomfort and even ... of therapies available for the prevention and treatment of angioedema, and ... acute attacks on this patient population. , , ...
... Calls on Congress to Enact Reform , ... Liability and Access today commended President Obama for acknowledging the need ... Congress to follow the President,s leadership by including reform in pending ... an address to Congress, President Obama said, "I,ve talked to enough ...
... , , , ... announced today that it has established the Edward Neurosciences Institute ... the highest level of stroke care in the world to ... (Photo: http://www.newscom.com/cgi-bin/prnh/20090910/CG73991 ) , , ...
... , , GREEN ... to keep a strong, healthy immune system. That means getting enough ... there are body stressors you can,t avoid. Environmental toxins are all ... The effects of these toxins can result in a toxic burden ...
... , , NEW BRUNSWICK, ... New York Giants vs. Washington Redskins game this Sunday, September ... new fight: supporting PSE&G Children,s Specialized Hospital, an inpatient rehabilitation ... life-changing conditions. , , Through an ...
... , ... of Cosmetic Injectables Can be a Felony , ... New York, NY (Vocus) September 10, 2009 -- One year in prison ... cosmetic injectables. As recently as August 2009, five physicians, one nurse and a practice ...
Cached Medicine News:Health News:New Directions in Angioedema: A Focus on Supportive Care and Treatment Options 2Health News:Broad Health Coalition Applauds President Obama's Commitment to Medical Liability Reform 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 2Health News:Edward Announces New Neurosciences Institute in Partnership With Northwestern Medical Faculty Foundation 3Health News:The #1 Stay Healthy Secret - Whole Body Cleanse(TM) from Enzymatic Therapy 2Health News:PSE&G Children's Specialized Hospital and New York Giants Team Up to Offer Text to Donate Campaign 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 2Health News:Physicians Coalition for Injectable Safety Urges Reporting of Suspected Illegal Solicitation or Use of Botox, Restylane, Radiesse and Others 3
A simple solution to hand assisted laparoscopic surgery....
... The HandPort Systems non-adhesive ... during Hand-Assisted Laparoscopic Surgrery (HALS) ... touch, grasp, and palpate throughout. ... small as 6 cm, patients ...
... 200 series offers a range of ... The design delivers therapy to meet ... promote results in commercial and clinical ... differentiator in the SleepStyle 200 series ...
The SleepStyle 600 series with ThermoSmart delivers humidification with anti-rainout benefits. ThermoSmart technology offers a heated breathing tube that allows the constant delivery of optimal level...
Medicine Products: